Bridging therapy in the perioperative management of patients with drug-eluting stents

Reviews in Cardiovascular Medicine

Volumn 10, Issue 4, 2009, Pages 209-218

  Chou, Stanley ^a   Eshaghian, Shervin ^a   Lamer, Amanda ^a   Tran, Hai ^a   Dohad, Suhail ^a   Kaul, Sanjay ^a  

^a NONE

Author keywords

Anticoagulants; Clopidogrel; Drug eluting stent; Glycoprotein IIb IIIa inhibitors; Stent thrombosis

Indexed keywords

'TAXUS'; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYPHER; EPTIFIBATIDE; EVEROLIMUS; FIBRINOGEN RECEPTOR; HEPARIN; PACLITAXEL; RAPAMYCIN; TACROLIMUS; TIROFIBAN; UNCLASSIFIED DRUG; ZOTAROLIMUS; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADVERSE OUTCOME; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CORONARY STENT; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; NONHUMAN; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; REVIEW; STENT THROMBOSIS; THROMBOSIS PREVENTION; AGED; ARTICLE; DRUG ADMINISTRATION; FEMALE; INSTRUMENTATION; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURGERY; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649205885     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0498     Document Type: Review

References (41)

1. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a meta-analysis of randomized bare-metal-stent-controlled trials. Int J Cardiol. 2005;100: 119-123.
2. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369:667-678.
3. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745-754.
4. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
6. Chechi T, Vecchio S, Vittori G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis: a new group of high-risk patients. J Am Coll Cardiol. 2008;51: 2396-2402.
7. Schühlen H, Kastrati A, Pache J, et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol. 2001;37:2066-2073.
8. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
9. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331:496-501.
10. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
11. Sutton JM, Ellis SG, Roubin GS, et al. Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. Circulation. 1994;89:1126-1137.
12. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12.
13. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation. 2003;108:43-47.
14. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes: lessons learned, lessons awaited. J Am Coll Cardiol. 2006;47:2112-2115.
15. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108-2111.
16. Matsumoto D, Shite J, Shinke T, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J. 2007;28:961-967.
17. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-2441.
18. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172-209.
19. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007;50:e159-e241.
20. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49: 734-739.
21. Newsome LT, Kutcher MA, Gandhi SK, et al. A protocol for the perioperative management of patients with intracoronary drug-eluting stents. APSF Newsletter. 2006;21:81-82.
22. Broad L, Lee T, Conroy M, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth. 2007;98:19-22.
23. D'Urbano M, Barlocco F, Poli A. Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy. J Cardiovasc Med (Hagerstown). 2008;9:737-741.
24. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257:399-414.
25. Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology. 2003;110:1784-1788.
26. Nuttall GA, Santrach PJ, Oliver WC Jr, et al. The predictors of red cell transfusions in total hip arthroplasties. Transfusion. 1996;36:144-149.
27. Manning BJ, O'Brien N, Aravindan S, et al. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury. 2004;35:121-124.
28. Nuttall GA, Horlocker TT, Santrach PJ, et al. Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine (Phila Pa 1976). 2000;25:596-601.
29. Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery. 1994;35:1061-1064.
30. Mangano DT; for the Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309-1317.
31. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000;70:1986-1990.
32. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesth Analg. 2001;93:573-580.
33. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45:456-459.
34. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004;62:1187-1189.
35. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27: 2667-2674.
36. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:299S-339S.
37. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-2367.
38. McDonald SB, Renna M, Spitznagel EL, et al. Preoperative use of enoxaparin increases the risk of postoperative bleeding and reexploration in cardiac surgery patients. J Cardiothorac Vasc Anesth. 2005;19:4-10.
39. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and non-cardiac surgery - a prospective outcome study. Br J Anaesth. 2006;96:686-693.
40. Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA. 1991;265:86-90.
41. Scott WJ, Rode R, Castlemain B, et al. Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg. 1992;103:1001-1006.